Thaddeus S Block1, Harvey Kushner2, Ned Kalin3, Craig Nelson4, Joseph Belanoff5, Alan Schatzberg6. 1. Corcept Therapeutics, Inc, Menlo Park, California; Stanford University School of Medicine, Stanford, California. Electronic address: tblock@corcept.com. 2. Biomedical Computer Research Institute, Inc, Philadelphia, Pennsylvania. 3. University of Wisconsin School of Medicine and Public Health - Madison, Madison, Wisconsin. 4. University of California San Francisco, San Francisco, California. 5. Corcept Therapeutics, Inc, Menlo Park, California; Stanford University School of Medicine, Stanford, California. 6. Stanford University School of Medicine, Stanford, California.
Abstract
BACKGROUND:Patients with psychotic depression exhibit elevated cortisol levels. Competitively antagonizing cortisol at the glucocorticoid receptor with mifepristone demonstrated therapeutic benefit in early studies of patients with psychotic depression. We present a combined analysis of all controlled phase 2 and 3 studies to report antipsychotic differences between treatment with mifepristone or placebo and to evaluate the relative contributions to response of attaining an a priori-defined, high mifepristone plasma level and markers of glucocorticoid receptor antagonism (increases in adrenocorticotropin hormone and cortisol) with treatment. METHODS: Data from five similarly designed double-blind phase 2 or 3 studies evaluating the efficacy and safety of 7-day treatment with mifepristone for the psychotic symptoms of psychotic depression were pooled for analysis (mifepristone n = 833; placebo n = 627). Clinical assessments were performed at baseline and on days 7, 14, 28, 42, and 56. Mifepristone, adrenocorticotropin hormone, and cortisol samples were collected at baseline and day 7. RESULTS: Combined results demonstrated meaningful efficacy (p < .004) for mifepristone in reducing psychotic symptoms with wide safety margins. Patients in the a priori-defined, high mifepristone plasma level group (≥1637 ng/mL) demonstrated a more significant treatment effect over placebo (p = .0004). A number needed to treat of 7 and 48 was observed in the high and low mifepristone plasma level groups, respectively. Adverse events were similar in mifepristone- and placebo-treated patients. CONCLUSIONS: A high mifepristone plasma level carried the strongest association with response, followed by changes in adrenocorticotropin hormone and cortisol. Therapeutic plasma levels of mifepristone were most likely to be achieved with the 1200 mg/day dose.
RCT Entities:
BACKGROUND:Patients with psychotic depression exhibit elevated cortisol levels. Competitively antagonizing cortisol at the glucocorticoid receptor with mifepristone demonstrated therapeutic benefit in early studies of patients with psychotic depression. We present a combined analysis of all controlled phase 2 and 3 studies to report antipsychotic differences between treatment with mifepristone or placebo and to evaluate the relative contributions to response of attaining an a priori-defined, high mifepristone plasma level and markers of glucocorticoid receptor antagonism (increases in adrenocorticotropin hormone and cortisol) with treatment. METHODS: Data from five similarly designed double-blind phase 2 or 3 studies evaluating the efficacy and safety of 7-day treatment with mifepristone for the psychotic symptoms of psychotic depression were pooled for analysis (mifepristone n = 833; placebo n = 627). Clinical assessments were performed at baseline and on days 7, 14, 28, 42, and 56. Mifepristone, adrenocorticotropin hormone, and cortisol samples were collected at baseline and day 7. RESULTS: Combined results demonstrated meaningful efficacy (p < .004) for mifepristone in reducing psychotic symptoms with wide safety margins. Patients in the a priori-defined, high mifepristone plasma level group (≥1637 ng/mL) demonstrated a more significant treatment effect over placebo (p = .0004). A number needed to treat of 7 and 48 was observed in the high and low mifepristone plasma level groups, respectively. Adverse events were similar in mifepristone- and placebo-treated patients. CONCLUSIONS: A high mifepristone plasma level carried the strongest association with response, followed by changes in adrenocorticotropin hormone and cortisol. Therapeutic plasma levels of mifepristone were most likely to be achieved with the 1200 mg/day dose.
Authors: Jennifer B Dwyer; Awais Aftab; Rajiv Radhakrishnan; Alik Widge; Carolyn I Rodriguez; Linda L Carpenter; Charles B Nemeroff; William M McDonald; Ned H Kalin Journal: Am J Psychiatry Date: 2020-05-27 Impact factor: 18.112
Authors: Stephanie A Carmack; Janaina C M Vendruscolo; M Adrienne McGinn; Jorge Miranda-Barrientos; Vez Repunte-Canonigo; Gabriel D Bosse; Daniele Mercatelli; Federico M Giorgi; Yu Fu; Anthony J Hinrich; Francine M Jodelka; Karen Ling; Robert O Messing; Randall T Peterson; Frank Rigo; Scott Edwards; Pietro P Sanna; Marisela Morales; Michelle L Hastings; George F Koob; Leandro F Vendruscolo Journal: Mol Psychiatry Date: 2022-03-16 Impact factor: 13.437
Authors: Vanessa A Jimenez; Nicole A R Walter; Tatiana A Shnitko; Natali Newman; Kaya Diem; Lauren Vanderhooft; Hazel Hunt; Kathleen A Grant Journal: J Pharmacol Exp Ther Date: 2020-09-01 Impact factor: 4.030
Authors: Felipe A Jain; Colm G Connolly; Victor I Reus; Dieter J Meyerhoff; Tony T Yang; Synthia H Mellon; Scott Mackin; Christina M Hough; Alexandra Morford; Owen M Wolkowitz Journal: Psychoneuroendocrinology Date: 2019-07-26 Impact factor: 4.905